[{"iD":0,"description":"No diagnosis.","abbreviation":"Unsat","bethesda2001":1,"bethesda2001ID":0,"gradeLevel":1,"objectId":"55438f9a3132350043002b0c","timestamp":"2017-02-16T19:14:28.363Z"},{"iD":1,"description":"Negative for intraepithelial lesion or malignancy.","abbreviation":"NILM","bethesda2001":1,"bethesda2001ID":1,"gradeLevel":1,"objectId":"55438f9a3132350043002b0d","timestamp":"2017-02-16T19:14:28.363Z"},{"iD":2,"description":"Reactive cellular changes;  no dysplasia seen.","abbreviation":"RCC","bethesda2001":0,"bethesda2001ID":-1,"gradeLevel":1,"objectId":"55438f9a3132350043002b0e","timestamp":"2017-02-16T19:14:28.367Z"},{"iD":3,"description":"Atypical squamous cells - uncertain significance (ASC-US).","abbreviation":"ASC-US","bethesda2001":1,"bethesda2001ID":2,"gradeLevel":2,"objectId":"55438f9a3132350043002b0f","timestamp":"2017-02-16T19:14:28.372Z"},{"iD":4,"description":"Low grade squamous intraepithelial (LSIL) - including HPV/mild dysplasia/(CIN 1)","abbreviation":"LSIL","bethesda2001":1,"bethesda2001ID":4,"gradeLevel":3,"objectId":"55438f9a3132350043002b10","timestamp":"2017-02-16T19:14:28.379Z"},{"iD":5,"description":"Low grade SIL (CIN 1 - mild dysplasia).","abbreviation":"LGSIL(CIN1)","bethesda2001":0,"bethesda2001ID":-1,"gradeLevel":3,"objectId":"55438f9a3132350043002b11","timestamp":"2017-02-16T19:14:28.385Z"},{"iD":6,"description":"High grade squamous intraepithelial lesion (HSIL) - including moderate (CIN 2) and severe dysplasia (CIN 3), CIS","abbreviation":"HGSIL","bethesda2001":1,"bethesda2001ID":5,"gradeLevel":4,"objectId":"55438f9a3132350043002b12","timestamp":"2017-02-16T19:14:28.392Z"},{"iD":7,"description":"High grade SIL (CIN 3 - severe dysplasia).","abbreviation":"HGSIL(CIN3)","bethesda2001":0,"bethesda2001ID":-1,"gradeLevel":4,"objectId":"55438f9a3132350043002b13","timestamp":"2017-02-16T19:14:28.394Z"},{"iD":8,"description":"High grade SIL (CIS - carcinoma in situ).","abbreviation":"HGSIL(CIS)","bethesda2001":0,"bethesda2001ID":-1,"gradeLevel":4,"objectId":"55438f9a3132350043002b14","timestamp":"2017-02-16T19:14:28.394Z"},{"iD":9,"description":"Squamous cell carcinoma.","abbreviation":"SCC","bethesda2001":1,"bethesda2001ID":6,"gradeLevel":4,"objectId":"55438f9a3132350043002b15","timestamp":"2017-02-16T19:14:28.395Z"},{"iD":10,"description":"Atypical glandular cells.","abbreviation":"AGUS","bethesda2001":1,"bethesda2001ID":7,"gradeLevel":4,"objectId":"55438f9a3132350043002b16","timestamp":"2017-02-16T19:14:28.396Z"},{"iD":11,"description":"Endocervical adenocarcinoma.","abbreviation":"CA","bethesda2001":0,"bethesda2001ID":-1,"gradeLevel":4,"objectId":"55438f9a3132350043002b17","timestamp":"2017-02-16T19:14:28.396Z"},{"iD":12,"description":"Endometrial adenocarcinoma.","abbreviation":"CA","bethesda2001":0,"bethesda2001ID":-1,"gradeLevel":4,"objectId":"55438f9a3132350043002b18","timestamp":"2017-02-16T19:14:28.397Z"},{"iD":13,"description":"Adenocarcinoma.","abbreviation":"CA","bethesda2001":1,"bethesda2001ID":9,"gradeLevel":4,"objectId":"55438f9a3132350043002b19","timestamp":"2017-02-16T19:14:28.398Z"},{"iD":14,"description":"Other malignant neoplasm.","abbreviation":"CA","bethesda2001":1,"bethesda2001ID":10,"gradeLevel":4,"objectId":"55438f9a3132350043002b1a","timestamp":"2017-02-16T19:14:28.399Z"},{"iD":15,"description":"Atypical squamous cells - cannot exclude high grade dysplasia (ASC-H).","abbreviation":"ASC-H","bethesda2001":1,"bethesda2001ID":3,"gradeLevel":4,"objectId":"55438f9a3132350043002b1b","timestamp":"2017-02-16T19:14:28.399Z"},{"iD":16,"description":"Endocervical adenocarcinoma-in-situ (AIS).","abbreviation":"AIS","bethesda2001":1,"bethesda2001ID":8,"gradeLevel":4,"objectId":"55438f9a3132350043002b1c","timestamp":"2017-02-16T19:14:28.400Z"}]